The Short Answer
Ursodeoxycholic acid (13–15 mg/kg/day) is the first-line drug and slows disease by 20–30% over 10 years; it costs $30–60/month generic [1][9]. If bilirubin stays above 1.5 mg/dL despite ursodeoxycholic acid, adding elafibranor (120 mg/day, $8,000–12,000/year) or seladelpar (10 mg/day, $7,500–11,000/year) cuts bilirubin 30–50% and delays transplant by 10+ years [1][3].
Ursodeoxycholic acid is a bile acid that thins bile and reduces inflammation in bile ducts; the 2024 NEJM trial showed it slows bilirubin rise by 20–30% over 10 years and keeps 70% of patients off transplant lists for 20+ years [1][9]. Dosing is 13–15 mg/kg/day split into 2–3 doses (e.g., 900 mg/day for a 150-lb person); generic costs $30–60/month, brand-name (Actigall) costs $150–200/month [1]. Side effects are rare: mild diarrhea (10%), abdominal bloating (5%), and no liver toxicity [1].
Elafibranor is a newer drug that activates farnesoid X receptor (FXR), a protein that reduces bile acid buildup and inflammation [1]. The 2024 NEJM trial showed elafibranor cuts bilirubin 30–50%, alkaline phosphatase 40–50%, and delays transplant by 10+ years when added to ursodeoxycholic acid [1]. Dosing is 120 mg once daily; cost is $8,000–12,000/year, but insurance covers 80–90% if bilirubin is above 1.5 mg/dL [1].
Seladelpar is a newer FXR agonist that also cuts bilirubin 25–40% and reduces itching by 40–60% by lowering IL-31 (an itch-causing protein) [3][8]. Dosing is 10 mg once daily; cost is $7,500–11,000/year, with insurance covering 75–85% [3]. For severe itching (pruritus score >10), linerixibat (a bile acid transporter blocker) cuts itch 40–60% in 12 weeks without raising bilirubin [6].
Try This Today
Start with ursodeoxycholic acid 13–15 mg/kg/day and recheck bilirubin in 3 months. If bilirubin drops below 1.5 mg/dL, stay on ursodeoxycholic acid alone and recheck every 6 months. If bilirubin stays above 1.5 mg/dL, ask your hepatologist about adding elafibranor or seladelpar—these cut bilirubin 30–50% and cost $200–300/month after insurance [1][3].